Browsing Category
Pharma Industry News
4729 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
HUTCHMED gets priority review for fanregratinib in FGFR2-positive cholangiocarcinoma in China
HUTCHMED’s fanregratinib gains NDA acceptance with priority review in China. Find out what it means for FGFR2-driven cancers and precision oncology adoption.
FDA clears mAbxience and Amneal’s denosumab biosimilars: What it means for the bone health and oncology market
Find out how Amneal and mAbxience’s FDA-approved biosimilars to Prolia and XGEVA could reshape the bone health and cancer care markets in the U.S.
FDA green light fast-tracks Diamyd Medical’s type 1 diabetes verdict by nine months
Diamyd Medical accelerates its Phase 3 type 1 diabetes trial after FDA alignment. Find out what the earlier data readout means for approval prospects.
Johnson & Johnson discontinues JNJ-5939 after DUPLEX-AD trial misses efficacy threshold in atopic dermatitis
Johnson & Johnson has discontinued JNJ-5939 in atopic dermatitis after interim trial results fell short of efficacy benchmarks. Find out what this means for the pipeline.
Can early access to GS010 in Israel accelerate GenSight’s push toward full regulatory approval?
GenSight Biologics secures Israeli early access for GS010 gene therapy in LHON. Find out how this could reshape access, manufacturing, and investor outlook.
Island Pharmaceuticals (ASX: ILA) awaits FDA clearance for Galidesivir as Animal Rule review enters final phase
Island Pharmaceuticals confirms no FDA setbacks on Galidesivir. Find out what this means for its Marburg virus study and broader regulatory strategy.
Japan approves Minjuvi for relapsed follicular lymphoma: What does this dual-CD immunotherapy mean for the market?
Incyte’s Minjuvi gets Japan approval for relapsed FL. Find out how this dual-CD regimen is reshaping immunotherapy options in a high-need market.
Curasight enters clinic with uTREAT for glioblastoma, advancing dual radiopharma strategy
Curasight starts first-in-human trial of uTREAT in glioblastoma, launching its therapeutic radiopharmaceutical program. Read the full strategic analysis.
Hoth Therapeutics (NASDAQ: HOTH) stakes claim on emerging oncodermatology space with dual patent filings for HT-001
Hoth Therapeutics files dual patents for HT-001 in oncology dermatology. Find out what this means for its IP strategy and cancer care positioning.
The inside story behind Samsung Bioepis’ European biosimilar takeover
Samsung Bioepis reclaims control of BYOOVIZ in Europe from Biogen, launching its own brand with a PFS version due in 2026. Read what this means for biosimilars.